The latest news from French healthcare and pharma, including an update on the hospital crisis; MaaT Pharma and Skyepharma's new cGMP microbiome facility; Sanofi's offloading of central nervous system drugs to Pharmanovia and Servier's EUR 120 million investment in its…
After offloading its consumer healthcare division in 2022 and in view of the gradual erosion of its top seller, Somatuline, Ipsen opted to aggressively seek external assets to enrich its…
The Contract Development and Manufacturing Organization (CDMO) sector has flousished in recent years as Big Pharma has shifted its attention to its core R&D activities and outsourced other supply chain…
Just five months after taking office, Aurélien Rousseau resigned from his role as health minister in protest against France’s recently adopted immigration law. Interim replacement Agnès Firmin Le Bodo, the…
Lionel Collet, president of France’s Haute Autorité de Santé (HAS), explains the role of the independent public authority, which extends beyond health technology assessment (HTA) to clinical practice guidelines and…
As president of the French League Against Cancer, Dr Daniel Nizri highlights the organization’s 106-year legacy of fighting cancer through research funding, health promotion, patient support, and advocacy. He discusses…
FACOPHAR Santé is the French association for actors operating in the natural and herbal remedies field. In conversation with PharmaBoardroom, long-term president Jacques Vernin explains how the organisation promotes French…
In the French government’s recent cabinet reshuffle, prime minister Elisabeth Borne’s former chief of staff, Aurélien Rousseau was appointed as the new minister of health. Rousseau, having piloted the Île-de-France…
France’s life sciences industry is falling behind its European neighbours, its growth deeply hampered, the French life sciences think tank G5 Santé claims, by abusive paybacks. While the government has…
France is the third most significant clinical research destination in Europe, participating in 50 percent of the trials initiated across the continent. While favourable government policies and unique strengths such…
The biggest stories from French healthcare and pharma, including AstraZeneca’s acquisition of Amolyt Pharma; protests over Sanofi layoffs; Pierre Fabre’s purchase of Kinnate Biopharma’s experimental pan-RAF inhibitor, and French biotech…
With revenues projected to reach USD 27.01 billion in 2024, France’s pharma market is ranked fifth globally. Home to a number of well-established local pharma players and a sought-after destination…
Despite an uncertain macro-economic environment, the French health technology sector continues its growth trajectory, demonstrating both entrepreneurial dynamism and maturity, according to the new edition of the France Biotech study…
See our Cookie Privacy Policy Here
